Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (11-20 of 224) with videos related to

Pageof 23
Sort By:
The Lancet. Oncology|April 4, 2017
Rushing will not help to choose the best combinationAlfredo Addeo, Bishal Gyawali
The Lancet. Oncology|December 1, 2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancerTimothée Olivier, Alfredo Addeo
The European Respiratory Journal|April 6, 2018
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 diseaseAlfredo Addeo, Giuseppe Banna
Praxis|March 1, 2023
Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)Geoffrey Merle, Alfredo Addeo
Translational Lung Cancer Research|September 27, 2019
Measuring tumor mutation burden in cell-free DNA: advantages and limitsAlfredo Addeo, Glen J Weiss
Case Reports in Oncology|July 31, 2013
Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patientAlfredo Addeo, Ciro Roberto Rinaldi
The New England Journal of Medicine|October 23, 2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLCGiuseppe Luigi Banna, Alfredo Addeo
Med (New York, N.Y.)|November 9, 2024
ADRIATIC: When face value is enoughAlfredo Addeo, Stephen V Liu
The New England Journal of Medicine|February 28, 2019
Atezolizumab plus Chemotherapy in Small-Cell Lung CancerGlen J Weiss, Alfredo Addeo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2018
Statistical and Clinical Significance in the TERRA StudyPaola Di Nardo, Alfredo Addeo
Pageof 23

Showing results (11-20 of 224) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|April 4, 2017
Rushing will not help to choose the best combinationAlfredo Addeo, Bishal Gyawali
The Lancet. Oncology|December 1, 2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancerTimothée Olivier, Alfredo Addeo
The European Respiratory Journal|April 6, 2018
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 diseaseAlfredo Addeo, Giuseppe Banna
Praxis|March 1, 2023
Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)Geoffrey Merle, Alfredo Addeo
Translational Lung Cancer Research|September 27, 2019
Measuring tumor mutation burden in cell-free DNA: advantages and limitsAlfredo Addeo, Glen J Weiss
Case Reports in Oncology|July 31, 2013
Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patientAlfredo Addeo, Ciro Roberto Rinaldi
The New England Journal of Medicine|October 23, 2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLCGiuseppe Luigi Banna, Alfredo Addeo
Med (New York, N.Y.)|November 9, 2024
ADRIATIC: When face value is enoughAlfredo Addeo, Stephen V Liu
The New England Journal of Medicine|February 28, 2019
Atezolizumab plus Chemotherapy in Small-Cell Lung CancerGlen J Weiss, Alfredo Addeo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2018
Statistical and Clinical Significance in the TERRA StudyPaola Di Nardo, Alfredo Addeo
Pageof 23